Evaluating the Significance of CDK2-PELP1 Axis in Tumorigenesis and Hormone Therapy Resistance

2011 ◽  
Author(s):  
Binoj Nair
Keyword(s):  
Hormone Therapy ◽  
Therapy Resistance

scholarly journals A Novel MAPK–microRNA Signature Is Predictive of Hormone-Therapy Resistance and Poor Outcome in ER-Positive Breast Cancer

2014 ◽  
Vol 21 (2) ◽  
pp. 373-385 ◽  
Author(s):  
Philip C. Miller ◽  
Jennifer Clarke ◽  
Tulay Koru-Sengul ◽  
Joeli Brinkman ◽  
Dorraya El-Ashry
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Therapy Resistance ◽  
Poor Outcome ◽  
Er Positive ◽  
Positive Breast Cancer

scholarly journals The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1028 ◽  
Author(s):  
David Rodriguez ◽  
Marc Ramkairsingh ◽  
Xiaozeng Lin ◽  
Anil Kapoor ◽  
Pierre Major ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cells ◽  
Estrogen Receptor ◽  
Cancer Stem Cells ◽  
Hormone Therapy ◽  
Endocrine Therapy ◽  
Endocrine Resistance ◽  
Therapy Resistance ◽  
Breast Cancer Stem Cells ◽  
Er Positive

Breast cancer stem cells (BCSC) play critical roles in the acquisition of resistance to endocrine therapy in estrogen receptor (ER)-positive (ER + ve) breast cancer (BC). The resistance results from complex alterations involving ER, growth factor receptors, NOTCH, Wnt/β-catenin, hedgehog, YAP/TAZ, and the tumor microenvironment. These mechanisms are likely converged on regulating BCSCs, which then drive the development of endocrine therapy resistance. In this regard, hormone therapies enrich BCSCs in ER + ve BCs under both pre-clinical and clinical settings along with upregulation of the core components of “stemness” transcriptional factors including SOX2, NANOG, and OCT4. SOX2 initiates a set of reactions involving SOX9, Wnt, FXY3D, and Src tyrosine kinase; these reactions stimulate BCSCs and contribute to endocrine resistance. The central contributions of BCSCs to endocrine resistance regulated by complex mechanisms offer a unified strategy to counter the resistance. ER + ve BCs constitute approximately 75% of BCs to which hormone therapy is the major therapeutic approach. Likewise, resistance to endocrine therapy remains the major challenge in the management of patients with ER + ve BC. In this review we will discuss evidence supporting a central role of BCSCs in developing endocrine resistance and outline the strategy of targeting BCSCs to reduce hormone therapy resistance.

Modulation of hormone therapy resistance by CDK2-PELP1 axis.

2009 ◽  
Author(s):  
B Chandrasekharan Nair ◽  
SS Nair ◽  
D Chakravarty ◽  
RP Yew ◽  
RR Tekmal ◽  
...  
Keyword(s):  
Hormone Therapy ◽  
Therapy Resistance

scholarly journals Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes

2020 ◽  
Author(s):  
Kathryn E. Ware ◽  
Santosh Gupta ◽  
Jared Eng ◽  
Gabor Kemeny ◽  
Bhairavy J. Puviindran ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Therapy ◽  
P38 Mapk ◽  
Mapk Pathway ◽  
Natural Populations ◽  
Resource Depletion ◽  
Therapy Resistance ◽  
New Locations ◽  
Hormone Resistant Prostate Cancer ◽  
Survival Mechanisms

SummaryAdaptation of cancer cells to targeted therapy follows ecological paradigms observed in natural populations that encounter resource depletion and changing environments, including activation of pro-survival mechanisms, migration to new locations, and escape of predation. We identified the p38 MAPK pathway as a common molecular driver of these three responses during the adaptation to hormone therapy resistance in prostate cancer. The p38 pathway is activated in therapy-resistant cells and mechanistically drives these three convergent responses through sustained AR activity, enhanced invasion and metastasis, and immune evasion. Targeting p38 signaling may represent a new therapeutic strategy to treat men with metastatic, hormone therapy-resistant prostate cancer.

scholarly journals Detection of Estrogen Responsive Breast Cancer Circulating Tumor Cells: Assay Development for Anti-Hormone Therapy Resistance

2015 ◽  
Vol 06 (09) ◽  
pp. 773-782
Author(s):  
Sally A. Litherland ◽  
Louis Barr ◽  
Robert Reynolds ◽  
Elizabeth Griffith ◽  
Ryan Sause ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Therapy Resistance ◽  
Assay Development
Sign in / Sign up

Export Citation Format

Share Document